Citi Raises Arcus Biosciences Price Target to $54 on Promising Cancer Drug Data
Citi upgrades Arcus Biosciences price target to $54 following impressive Phase 2 cancer treatment results showing 26.7 months median survival in gastric cancer patients.
Citi upgrades Arcus Biosciences price target to $54 following impressive Phase 2 cancer treatment results showing 26.7 months median survival in gastric cancer patients.
Casdatifan data is a "home run"! Survival without disease worsening hit 12 months, which is double the competitor's time.